ALERTS: MERGERS - EUROPEAN UNION - FRANCE - HEALTHCARE - ARTICLE 22 REFERRALS - THRESHOLDS

Referral: The European Commission opens in-depth investigation into proposed acquisition of startup that developed blood tests capable of detecting around 50 very early-stage cancers (Illumina / Grail)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. Despite the appeal filed by US-based Illumina against the Commission's decision of 19 April 2021 (not yet published) in which the Commission accepted the Competition Authority's 9 March 2021 request for a referral under Article 22(1) of the EC Merger Regulation

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • L’actu-concurrence (Paris)

Quotation

Alain Ronzano, Referral: The European Commission opens in-depth investigation into proposed acquisition of startup that developed blood tests capable of detecting around 50 very early-stage cancers (Illumina / Grail), 22 July 2021, Concurrences N° 3-2021, Art. N° 101785, www.concurrences.com

Visites 59

All reviews